DT
HealthMore in Health→
Remission Antibodies Point to a New CAR T Strategy Against Acute Myeloid Leukemia
Key Takeaways
- Researchers used antibodies from AML patients in long-term remission after bone marrow transplant to identify a new target.
- The target, U5 snRNP200, appears on the surface of leukemia cells in about half of AML patients but is usually found inside the nucleus.
- Engineered CAR T cells showed activity in animal models and appeared broadly effective against several other leukemia types.
DE
DT Editorial Team··via medicalxpress.com
